Drugs Made In America Acquisition II Right (DMIIR) Stock Price, News & Analysis
Price Move History
- Daily moves over 5%
- 63 132 sessions, December 3, 2025 to September 14, 2026
- Largest daily move
- +24.7% close of August 17, 2026
Company Description
Drugs Made In America Acquisition II Right (NASDAQ: DMIIR) is classified in the blank checks industry.
DMIIR has declined 46.5% so far this year. The last closing price was $0.0749.
For FY2025, Drugs Made In America Acquisition II Right reported net income of $4.2M.
This page collects what Stock Titan holds for DMIIR, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Drugs Made In America Acquisition II Right (DMIIR) closed at $0.0749 on September 14, 2026. So far this year, the price has lost 46.5%.
DMIIR Metrics & Rankings
Price returns through September 14, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
SEC Filings
Drugs Made In America Acquisition II Right has filed 5 recent SEC filings, including 2 Form 10-Q, 2 Form 8-K, 1 Form 10-K. The most recent filing was submitted on August 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all DMIIR SEC filings →
Financial Highlights
operating income reached -$488K, and net income was $4.2M. The company generated -$1.0M in operating cash flow. With a current ratio of 0.09, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Short interest in Drugs Made In America Acquisition II Right (DMIIR) currently stands at 15.3 thousand shares, down 23.8% from the previous reporting period. Since December 2025, short interest has increased by 3734.0%.
Days to Cover History
Days to cover for Drugs Made In America Acquisition II Right (DMIIR) currently stands at 2.4 days, down 70.6% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 139% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.0 to 11.7 days.
DMIIR Company Profile & Sector Positioning
Drugs Made In America Acquisition II Right (DMIIR) and is listed on the NASDAQ.